ASH 2019 (MDS/AML)
MDS and AML Research Summaries for Patients from the 2019 American Society of Hematology Annual Meeting
Acute Myeloid Leukemia (AML)
ASH 2018 (MDS/AML)
MDS and AML Research Summaries for Patience from the 2018 American Society of Hematology Annual Meeting
EHA/ASCO 2019
Research Summaries for Patients from the 2019 European Hematology Association and the 2019 American Society of Clinical Oncology meetings
ASH 2020
Bone Marrow Failure Disease Research Summaries for Patients from the 2020 American Hematology Society Annual Meeting
AAMDS Scientific Symposium 2020
Summary for patients from the seventh International Bone Marrow Failure Disease Scientific Symposium
ASCO EHA 2021 Research Summaries (MDS/AML)
MDS and AML Research Summaries for Patients from the 2021 European Hematology association and the American Society of Clinical Oncology Annual Meetings
ASCO EHA 2020 Research Summaries (MDS/AML)
MDS and AML Research Summaries for Patients from the 2020 European Hematology association and the American Society of Clinical Oncology Meetings
VENCLEXTA Fact Sheet
Venclexta® (also known as Venetoclax) is a prescribed oral tablet approved by the Food and Drug Administration for adult patients with acute myeloid leukemia (AML)
Order Patient Educational Materials
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure
Outpatient Low-Dose Venetoclax-Azacitidine vs. Intensive Therapy in Newly Diagnosed AML in Resource-Limited Settings
Original Publication Date
Article Source
External Web Content
Key points Outpatient low-dose VenAza plus itraconazole reduced early mortality and hospitalizations while maintaining treatment efficacy. VenAza offers a safer, cost-effective alternative to intensive chemotherapy in newly diagnosed AML. Abstract Acute myeloid leukemia (AML)…